Xin-Fu-Kang oral liquid improves cardiac function and attenuates miR-223-associated NF-κB/NLRP3 pyroptotic signaling

Zelin Ye1, Mingrui Liu2, Xiaohan Zhang1

  • 1Department of Cardiology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.

Frontiers in Pharmacology
|December 29, 2025
PubMed

Insights

Xin-Fu-Kang (XFK) protects against chronic heart failure (CHF) by modulating pyroptotic signaling. This traditional Chinese medicine formula upregulates miR-223, which inhibits NF-κB and NLRP3 inflammasome activation, reducing inflammation and improving cardiac function.

Area of Science:

  • Cardiovascular Research
  • Molecular Biology
  • Inflammation Research

Background:

  • Pyroptotic signaling, involving nuclear factor-kappa B (NF-κB) and NOD-like receptor family pyrin domain-containing 3 (NLRP3), is implicated in chronic heart failure (CHF).
  • Xin-Fu-Kang (XFK), a traditional Chinese nine-herb formula, is clinically used for CHF characterized by "qi deficiency and blood stasis."
  • The precise mechanism by which XFK modulates myocardial pyroptotic signaling, particularly via miR-223 regulation of NF-κB, remains unclear.

Purpose of the Study:

  • To investigate whether Xin-Fu-Kang (XFK) modulates myocardial pyroptotic signaling in chronic heart failure (CHF).
  • To determine the role of miR-223 in mediating the effects of XFK on NF-κB and NLRP3 inflammasome activation in CHF.
  • To elucidate the potential of XFK as an adjunctive therapy for inflammation-driven cardiac dysfunction.

Main Methods:

  • Established a rat model of CHF via coronary artery ligation and an in vitro oxygen-glucose deprivation/reoxygenation (OGD/R) model in H9c2 cardiomyocytes.
  • Assessed cardiac function, structure, inflammation (IL-1β, IL-18), and pyroptotic markers (NLRP3, caspase-1, ASC, GSDMD-N, NF-κB p65 phosphorylation/translocation).
  • Utilized miR-223 gain- and loss-of-function studies, including inhibitor rescue experiments, to establish causality.

Main Results:

  • XFK treatment improved cardiac function and structure, reduced myocardial inflammation, fibrosis, and cardiomyocyte apoptosis in the CHF model.
  • XFK attenuated OGD/R-induced injury in cardiomyocytes by suppressing NLRP3 inflammasome activation and NF-κB signaling.
  • XFK upregulated miR-223 expression, and miR-223 overexpression mimicked XFK's protective effects, while miR-223 inhibition abrogated them, indicating a miR-223-dependent mechanism.

Conclusions:

  • NF-κB-linked NLRP3 pyroptotic signaling is a key feature of the studied CHF model.
  • XFK exerts cardioprotective effects in CHF by modulating NF-κB/NLRP3 pyroptotic signaling through a miR-223-dependent pathway.
  • XFK shows potential as an adjunctive therapeutic strategy to mitigate inflammation-driven cardiac dysfunction in CHF.
Abstract

Related Concept Videos

Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
196
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.2K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
874
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
233
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
763